C WorldWide Group Holding A S Acquires 100,000 Shares of Insmed, Inc. $INSM

C WorldWide Group Holding A S grew its stake in shares of Insmed, Inc. (NASDAQ:INSM) by 62.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 261,110 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the quarter. Insmed accounts for approximately 0.7% of C WorldWide Group Holding A S’s portfolio, making the stock its 25th largest holding. C WorldWide Group Holding A S’s holdings in Insmed were worth $27,840,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. CIBC Private Wealth Group LLC lifted its stake in shares of Insmed by 42.1% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in Insmed by 10.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 747 shares of the biopharmaceutical company’s stock worth $130,000 after acquiring an additional 69 shares during the last quarter. Private Advisor Group LLC increased its stake in Insmed by 1.8% in the 1st quarter. Private Advisor Group LLC now owns 4,749 shares of the biopharmaceutical company’s stock worth $777,000 after purchasing an additional 82 shares during the period. Glenmede Trust Co. NA increased its stake in Insmed by 5.4% in the 1st quarter. Glenmede Trust Co. NA now owns 1,916 shares of the biopharmaceutical company’s stock worth $313,000 after purchasing an additional 98 shares during the period. Finally, Allworth Financial LP increased its stake in Insmed by 20.5% in the 4th quarter. Allworth Financial LP now owns 635 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 108 shares during the period.

Insmed Stock Down 1.1%

Shares of NASDAQ INSM opened at $124.89 on Wednesday. The company has a current ratio of 3.72, a quick ratio of 3.40 and a debt-to-equity ratio of 0.74. Insmed, Inc. has a 12 month low of $90.39 and a 12 month high of $212.75. The firm has a market capitalization of $27.27 billion, a PE ratio of -30.39 and a beta of 0.82. The firm has a fifty day simple moving average of $116.65 and a two-hundred day simple moving average of $124.70.

Insmed (NASDAQ:INSM) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.61. The firm had revenue of $425.49 million during the quarter, compared to analysts’ expectations of $395.50 million. Insmed had a negative net margin of 76.94% and a negative return on equity of 123.94%. The company’s quarterly revenue was up 296.1% compared to the same quarter last year. During the same period last year, the company posted ($1.70) EPS. Equities analysts expect that Insmed, Inc. will post -1.83 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on INSM. HC Wainwright reissued a “buy” rating on shares of Insmed in a research note on Monday, August 10th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $175.00 target price on shares of Insmed in a research note on Thursday, August 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $235.00 price target on shares of Insmed in a report on Tuesday, July 28th. Royal Bank Of Canada dropped their price target on shares of Insmed from $205.00 to $195.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, UBS Group restated a “buy” rating and issued a $172.00 price objective on shares of Insmed in a research report on Friday, August 7th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $205.52.

Insider Buying and Selling

In other Insmed news, COO Roger Adsett sold 239,850 shares of the firm’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $133.27, for a total value of $31,964,809.50. Following the completion of the sale, the chief operating officer directly owned 98,744 shares in the company, valued at $13,159,612.88. This trade represents a 70.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Michael Smith sold 1,806 shares of Insmed stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $95.82, for a total value of $173,050.92. Following the sale, the insider directly owned 37,648 shares in the company, valued at approximately $3,607,431.36. The trade was a 4.58% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 273,753 shares of company stock valued at $35,604,764 over the last three months. Corporate insiders own 2.10% of the company’s stock.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.